Advanced Genetic Testing in Philippines for Cancer and Baby’s Health Launched Through Gene Solutions & The Medical City Partnership

Pasig City, Philippines – April 28, 2025 – Gene Solutions has teamed up with The Medical City (TMC), the largest healthcare network in the Philippines to bring advanced DNA testing closer to Filipino families. Through this partnership, a state-of-the-art Next-Generation Sequencing (NGS) facility is now operational at TMC Ortigas—offering faster, more affordable tests for cancer and prenatal screening.

For families who previously had to wait weeks and pay high fees to send DNA samples abroad, this partnership is a game-changer. Testing can now be done locally, with results available sooner and at lower cost.

 

Why This Matters for Filipino Patients

DNA testing used to be something only a few could access. But with NGS technology now available locally, more Filipinos can benefit from:

  • Early cancer screening – A simple blood test can detect signs of cancer even before symptoms appear.
  • Safe pregnancy screening – Mothers-to-be can check their baby’s health without risking the baby’s safety.
  • Personalized treatment – For patients already diagnosed with cancer, doctors can tailor treatments based on the unique genetic makeup of the tumor.

Gene Solutions has partnered with The Medical City — the largest healthcare network in the Philippines — to bring a state-of-the-art Next-Generation Sequencing (NGS) facility right here at home.

Available Tests Now at The Medical City

The partnership offers a range of advanced DNA tests that are now available locally:

  • triSure NIPT – A safe, non-invasive test during pregnancy to screen for common genetic conditions in the baby (like Down syndrome and certain rare disorders). No need for painful procedures.
  • SPOT-MAS – A blood test that can help in the bloodstream. This can help detect cancer even before any symptoms. The technology is also available for single-cancer screening, focusing on lung and colorectal cancers.
  • oncoGS – A test for patients with cancer to find out which treatments may work best based on their tumor’s unique genetic makeup.

 

Personalized Treatment, Better Outcomes Closer to Home

“Before this partnership, we had to send samples to Gene Solutions’ central laboratories in Singapore and Vietnam, which could result in longer wait times and higher logistics costs. Now, with our laboratory partnership with TMC, we are confident that this collaboration will bring significant benefits and greater accessibility to Filipino patients, Gene Solutions Philippines Director, Ms. Mary Josephine Rapadas, shared.

With the new local laboratory, results are delivered faster since there’s no need to send samples abroad. The cost of testing is also lower with the elimination of international shipping and handling fees. Free post-test counseling is also available to support patients every step of the way, offering expert guidance to help patients understand their results and decide on the next steps with confidence.

“This collaboration is part of The Medical City’s commitment to give patients access to medical innovations that can lead to better outcomes. By making DNA testing more accessible, we want to empower patients and families to make informed health decisions,” Dr. Ruben G. Kasala, Executive Vice President & CEO of TMC Ortigas, said.

These services will soon be available at other The Medical City hospitals and clinics nationwide, with all DNA samples processed locally at the Ortigas laboratory. This marks an important advancement in making proactive healthcare and personalized treatment more accessible to Filipinos.

To learn more, talk to your doctor at The Medical City or visit www.themedicalcity.com to book an appointment.

 

About The Medical City

The Medical City is the Philippines’ largest integrated healthcare network. It is composed of one flagship complex in Ortigas, five provincial hospitals (Clark, Laguna, Iloilo, Pangasinan, and Guam), and over 70 clinics nationwide. Annually, it serves over 2 million outpatients and 33,000 inpatients across the system.

With multiple Joint Commission International (JCI) accreditations, global benchmark certifications, and continued investment in innovation, The Medical City is building a healthcare system not just for today — but for the future of Filipino care.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More